Sartorius Stedim Biotech : Close to a key resistance level
| Entry price | Target | Stop-loss | Potential |
|---|
|
€408.4 |
€500 |
€335 |
+22.43% |
|---|
Sartorius Stedim Biotech is close to a major resistance level, whereby the breach of this level could be considered as a buy signal. This reflects our preferred scenario in light of the stock's current technical chart pattern.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
●
● The company returns high margins, thereby supporting business profitability.
● Over the last twelve months, the sales forecast has been frequently revised upwards.
● Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
●
●
●
● With an expected P/E ratio at 73.34 and 65.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● The company's "enterprise value to sales" ratio is among the highest in the world.
●
●
● The company is not the most generous with respect to shareholders' compensation.
●
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
SARTORIUS STEDIM BIOTECH 
